P70 s6 kinase inhibitors

A pharmaceutical formulation comprising a compound of the formula:

• wherein:
• Y is N or CR6;
• Z1 and Z2 are independently CR3 or N, provided that Z1 and Z2 are not both N;
• R1 is H or C1-C4 alkyl;
• R2 is phenyl optionally substituted with a first substituent selected from C1-C4 alkyloxy, cyano, NO2, halo, trifluoromethyl, and trifluoromethoxy and optionally further substituted with a second substituent selected from the group consisting of halo;
• R3 is hydrogen, halo, C1-C4 alkyl, C3-C6 cycloalkyl, or C2-C6 alkynyl, wherein
• C2-C6 alkynyl is optionally substituted with hydroxy;
• R4 and R5 are independently hydrogen or C1-C4 alkyl;
• R6 is hydrogen or hydroxy;
• or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.

A method for treating adenocarcinomas of the colon in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula:

• wherein:
• Y is N or CR6;
• Z1 and Z2 are independently CR3 or N, provided that Z1 and Z2 are not both N;
• R1 is H or C1-C4 alkyl;
• R2 is phenyl optionally substituted with a first substituent selected from C1-C4 alkyloxy, cyano, NO2, halo, trifluoromethyl, and trifluoromethoxy and optionally further substituted with a second substituent selected from the group consisting of halo;
• R3 is hydrogen, halo, C1-C4 alkyl, C3-C6 cycloalkyl, or C2-C6 alkynyl, wherein
• C2-C6 alkynyl is optionally substituted with hydroxy;
• R4 and R5 are independently hydrogen or C1-C4 alkyl;
• R6 is hydrogen or hydroxy;
• or a pharmaceutically acceptable salt thereof.